title: Efficiency and safety of long-term artrofoon treatment in rheumatoid arthritis.
abstract: In patients with rheumatoid arthritis, prolongation of artrofoon therapy to 2 years led to maintenance of the positive clinical effect attained after 6-month treatment. Moreover, significant improvement was observed by some parameters (integral pain intensity, swelling index, Ritchie articular index, morning stiffness, and articular score). No side effects related to artrofoon treatment were observed throughout the treatment period in the main group. The results indicate high efficiency and good tolerability of the preparation and attest to advisability of its long-term use.
authors.affiliation: Volgograd State Medical University, Federal Agency for Health Care and Social Development.
authors.forename: V I
authors.initials: VI
authors.lastname: Petrov
authors.forename: A R
authors.initials: AR
authors.lastname: Babaeva
authors.forename: E V
authors.initials: EV
authors.lastname: Cherevkova
authors.forename: M V
authors.initials: MV
authors.lastname: Kachanova
authors.forename: Yu A
authors.initials: YA
authors.lastname: Zabolotneva
authors.forename: S A
authors.initials: SA
authors.lastname: Tarasov
authors.forename: Yu L
authors.initials: YL
authors.lastname: Dugina
authors.forename: S A
authors.initials: SA
authors.lastname: Sergeeva
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; C503436:Artrofoon